| Name | Title | Contact Details |
|---|
IMIDomics is a biotechnology company focused on Patient-Centric drug discovery for immune-mediated inflammatory diseases (IMIDs). Our goal is to discover new and impactful IMID drugs by focusing on carefully selected patients, and stratifying populations to identify those most likely to respond. IMIDomics is powered by a unique Clinical Discovery EngineTM, which integrates and analyzes proprietary clinical, epidemiological and patient-derived biomolecular datasets, generated in partnership with the Vall d`Hebron Institute of Research, to establish a deeper understanding of IMID diseases. By doing so, IMIDomics has identified previously unrecognized targets, six of which have been selected for development. By relying on access to well-defined patients and their clinically relevant samples, IMIDomics enhances the probability of successful IMID drug discovery and development for those in need.
Founded in 2019, Totus Medicines uses revolutionary chemical biology to create life-changing therapies to treat previously untreatable diseases across the entire human genome. Totus is based in Cambridge, Massachusetts.
Pars Environmental is a Trenton, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Saneron CCEL Therapeutics is a Tampa, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
PharmaTech is a Fort Lauderdale, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.